🚨Trade Alert 🚨 NMTC

🚨Trade Alert 🚨 NMTC͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This quietly trading NASDAQ company priced around $1…. is targeting a multi-billion market opportunity…. Greetings Investors, Surgery... it’s often a procedure that scares people and makes them want to avoid it at all costs. In today’s modern world, healthcare is approaching surgical operations in a different manner. One that is giving many patients peace of mind. This is what makes one emerging company on the NASDAQ so exciting. Hurry and add NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) to your radar! NMTC is a medical tech company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The company is a developer of best-in-class electrodes designed to diagnose and treat debilitating neurological conditions with a multi-billion market opportunity for combination devices. The stock currently has [a high price target of $3.25]( representing an upside of over 100% compared to current levels! Minimally invasive surgery (otherwise known as MIS) has taken the forefront of the surgical industry and NMTC could come out as one of the key players in it. MIS presents a lot of benefits to patients compared to an open technique. The advantages range from reduced healthcare costs to smaller incisions, less scarring, increased accuracy, decreased risk of complications, less pain, and shorter recovery. The advent of laparoscopic surgery in the 1980s started a revolution in MIS, which is continuing to expand as more patients want to avoid having surgery. Today, MIS technology - like that of NMTC - is used in a wide range of procedures. This includes neurosurgery, gynecological, urological, and cardiovascular surgeries. NMTC has been committed to providing minimally invasive and hi-definition solutions that may improve patient outcomes and reduce procedural costs for electroencephalograms (EEG) and brain stimulation, and ablation solutions for patients who have: epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. In other words, the company is offering a revolutionary approach for people who suffer from countless neurological disorders. NMTC says it addresses current treatment challenges where electrodes are used to detect, record and monitor neurological activity and stimulate or ablate tissue to regulate brain activity. Contrary to the use of electrodes, the company believes its new radiofrequency (RF) ablation system ([OneRF® Ablation system]( may offer detection, recording, and treatment in a procedure leading to higher patient satisfaction, lower patient risk, lower cost and improved accuracy. Considering that the ablation devices market size [garnered]( over $8.6 billion in revenues in 2022 and is predicted to exhibit above 9% compound annual growth rate (CAGR) from 2023 to 2032, there is a massive market here! The company’s CEO Dave Rosa made an appearance on The Claman Countdown on Fox Business in February last year and highlighted the groundbreaking technology the company has been working on. This technology already has FDA clearance! Highlighting Elon Musk's Neuralink, which is building a brain chip interface that can be implanted within the skull, Rosa explained that NeuroOne's technology is less invasive, near term and less complicated compared to Neuralink, which is complex and several years away from going commercial. Watch the video on Fox Business for more [here](. Major players in the global minimally invasive surgery market include Medtronic PLC (NYSE: MDT), Intuitive Surgical Inc. (NASDAQ: ISRG), and Globus Medical Inc. (NYSE: GMED). Trading at under $2.00 and a market cap of just around $25M, NMTC could be strategically placed for growth and is a story to keep your eyes on! [( NeuroOne Medical Technologies Corp. NASDAQ: NMTC Company Overview: NMTC is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. Company Highlights: - The company has a marketing and distribution partnership with Zimmer Biomet Holdings Inc. (NYSE: ZBH) for diagnostic applications; Anticipated launch of [EVO® Cortical/EVO® sEEG]( electrodes in late Q1 2023 (more than $100 million market) - An anticipated U.S. regulatory submission (510k) of OneRF® Ablation system in Q2 2023; for use with EVO sEEG® electrodes to treat neurologic conditions. - Strategy to access the ablation market through additional partnerships leveraging the resources of commercial med tech companies; Zimmer has rights of first negotiation. - The company’s next-generation electrodes are in development for spinal cord and deep brain stimulation to treat chronic conditions such as Parkinson's disease, epilepsy, tremors, and chronic pain. - There is [a significant cash runway]( to achieve meaningful inflection points. Dave Rosa, CEO of NeuroOne: "We believe our technology can fill a market need for improved patient outcomes due in part to its potential ability to place a paddle device through a needle, provide a larger stimulation surface area of the spinal cord, better conformability with the tissue and improve battery life of devices, reducing the frequency of patient's need to recharge or replace the battery." Completion Of Initial Animal Implant of Novel Thin Film Paddle Lead For Spinal Cord Stimulation NMTC recently [completed]( initial animal implant of its novel thin film paddle lead for spinal cord stimulation and is developing a percutaneous (through a needle) paddle lead placement system, which could eliminate the need for an incision in the patient's back. The study evaluated the feasibility of implanting a variety of sizes and shapes of ultra-thin paddle leads in a sheep model. A mini laminectomy surgical approach was used to gain access to the epidural space for device placement. All devices were easily advanced to the target location in under one minute. A competitive silicone-based lead was also placed for comparison purposes. The NeuroOne lead fit comfortably in the epidural space and the veterinary surgeon reported no concerns regarding the placement of the lead.These results demonstrated feasibility for placement of a thin film paddle lead intended to treat chronic back pain due to multiple failed back surgeries. More testing will be completed to optimize the design and placement. The Company is also developing a percutaneous (through a needle) paddle lead placement system which would eliminate the need for an incision in the patient's back. The preliminary bench top testing for this percutaneous approach has also been successfully completed.This represents a major milestone for the company!NMTC says it is also developing a percutaneous (through a needle) paddle lead placement system, which would eliminate the need for an incision in the patient's back. The preliminary benchtop testing for this percutaneous approach has also been completed.Fiscal First Quarter 2023 and Recent Business Updates: - Received FDA 510(k) clearance to market the Evo® sEEG Electrode technology for temporary (less than 30 day) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, enabling NeuroOne to fully address the $100M diagnostic electrode market. - A feasibility animal study of the Company's OneRF® therapeutic radiofrequency ablation electrode system was completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN. OneRF is an sEEG probe-guided RF based system to monitor and adjust settings based on temperature throughout an ablation, a feature designed to improve the safety of the procedure. - The first commercial order of Evo® sEEG electrodes for temporary use (less than 30 days) was shipped to the Company's distribution and development partner Zimmer Biomet. NeuroOne continues to build up inventory to meet product forecasts and fulfill additional orders in-house. - The Company developed and successfully bench tested an early prototype of a first-of-a-kind device that can deliver drugs (or other diagnostic or therapeutic agents) to the brain while also having the capability to stimulate and record before and after application. - Held discussions with strategic organizations regarding the Company's technology in an effort to potentially expand the product footprint in neurology. - Exhibited the Evo electrode product family with Zimmer Biomet at the Congress of Neurological Surgeons annual meeting and the American Epilepsy Society and Congress of Neurological Surgeons annual meetings. - CEO Dave Rosa featured on Fox Business Network's 'Mornings with Maria.' - Rang Nasdaq Stock Market closing bell to commemorate the FDA clearance milestone for Evo sEEG Electrode technology. Upcoming Targeted Milestones: - Commercial launch of Evo sEEG electrodes with Zimmer Biomet in the first quarter of calendar year 2023. - Along with Zimmer Biomet, present the newly launched Evo sEEG system at the American Association of Neurological Surgeons (AANS) annual meeting at the end of April 2023. - Submit a 510(k) application to the FDA for OneRF in the second quarter of calendar year 2023. - Complete design verification testing for OneRF confirming that the full feature system meets its design specifications and is fully functional. - Complete next in vivo animal testing of the OneRF system with multiple surgeons with the objective of gathering additional in vivo data on the system's performance. - Pre-clinical implantation for spinal cord stimulation (SCS) electrodes intended for permanent implant to treat chronic pain. The Bottom Line: With the growing epidemic of neurological disorders from Epilepsy to Parkinson’s Disease, and even chronic back pain and depression… it has become apparent to pay close attention to the companies tackling such disorders! NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is an emerging and exciting player on the NASDAQ that is doing exactly just this! How is this essentially undiscovered company potentially about to revolutionize healthcare? NMTC has developed a breakthrough thin-film electrode. Thanks to strategic partnerships with Zimmer Biomet, the company anticipates that their technologies will be widely adopted in the near future. Why should this breakthrough company be on your watchlist? First, there is substantial market opportunity. Second, these are disruptive patented technologies. Third, the technology addresses a significant and unmet need and there could be substantially improved outcomes. AND… these are already FDA cleared electrodes! All of this reads like a recipe for success and NMTC may be one of the most exciting narratives to emerge on the NASDAQ that has a price target over 100% higher than current levels! Start your research right away! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in NMTC. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding NMTC with a start date of 5/01/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042